1st Circ. Spots 'Gap' In Cancer-Drug Suit Against Karyopharm
A First Circuit panel appeared receptive Tuesday to claims that Karyopharm Therapeutics Inc. executives gave an overly rosy assessment of negative drug trial results, but questioned whether investors could show the statements...To view the full article, register now.
Already a subscriber? Click here to view full article